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Stromal-derived factor (SDF)–1, the natural ligand for CXCR4, is present in a common
polymorphic variant defined by a GrA transition in the 3′ untranslated region of the gene.
In persons infected with human immunodeficiency virus type 1 (HIV-1), the homozygous
genotype (SDF1-3′A/3′A) has been postulated to interfere with the appearance of T-tropic
syncytium-inducing strains. The polymorphism of SDF1 was correlated with HIV-1 pheno-
type, plasma viremia, and unspliced and multiply spliced specific transcripts in 158 virolog-
ically characterized HIV-1–infected patients (39 recent seroconverters, 75 typical progressors,
and 44 AIDS patients) and in 42 HIV-1–infected long-term nonprogressors (LTNPs). Analysis
of SDF1 allele distribution revealed that SDF1-3′A/3′A status is associated with low CD4 cell
count ( ) but not with a specific HIV-1 phenotype. In LTNPs, SDF1-+/+ conditionP 5 .0449
defined a subset of persons with lower HIV-1 replication than in heterozygous subjects. The
low viral activity in SDF1-+/+ LTNPs suggests that other factors play a major role in vivo
in determining the course of HIV-1 infection.
An important advance in AIDS research is the demonstration
that human immunodeficiency virus type 1 (HIV-1) uses fam-
ilies of both a and b chemokine receptors as coreceptors for
entry into CD4 target cells [1]. These findings prompted the
research for polymorphism in chemokine receptor genes in
HIV-1–infected persons to assess the role of these molecules in
determining the course of infection [2–4]. Because, in most stud-
ies, the prevalence of CCR5-D32 heterozygosity is reduced in
AIDS patients, it has been suggested that the CCR5-D32 het-
erozygous condition is associated with nonprogression [2, 5, 6].
However, it has not been excluded that a combination of several
allelic forms of CCR genes may play a role in HIV-1 disease
progression [3, 7].
Stromal-derived factor (SDF)–1 is the natural ligand for
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CXCR4 [8]. Recently, a common polymorphic variant defined
by a GrA transition in the 3′ untranslated region (UTR) of
the SDF1 gene was investigated in five large cohorts. The results
suggested that the homozygous genotype (SDF1-3′A/3′A) is as-
sociated with a slow progression to AIDS in HIV-1–infected
persons [9]. In that cross-sectional study, a gradation of the
3′A/3′A genotype prevalence across increasingly severe AIDS
end points was observed, leading to the hypothesis that the
homozygous status may interfere with the appearance of T-
tropic syncytium-inducing (SI) HIV-1 strains. The mechanism
could involve the up-regulation of SDF1 protein, which com-
petes with HIV-1 to bind the CXCR4 receptor. However, a
recent retrospective study failed to identify a correlation be-
tween the SDF1 homozygous condition and the total frequency
of SI HIV-1 variants, although the prolonged survival after
AIDS diagnosis was confirmed in a population of homosexual
HIV-1–positive patients [10]. A subsequent study suggested that
progression to death, but not the clinical end point of AIDS,
is related to SDF1-3′A allelic status [11]. A clear correlation of
SDF1-3′A homozygosity with protection against disease pro-
gression was questioned in two other recent reports [12, 13].
Although additional evidence on the interaction between
HIV-1 and a and b chemokine receptors was provided by recent
crystallographic studies [14], no conclusive data are available
regarding the relationship between SDF1 genotype and levels
of viral replication in HIV-1–infected persons with typical or
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Table 1. SDF1 polymorphism in study population.
Group
SDF1 genotypea
Allelic frequency1/1 1/3′A 3′A/3′A
Healthy controls (n5105) 62 (59.0) 40 (38.1) 3 (2.9) 0.219
High-risk seronegative (n518) 11 (61.1) 6 (33.3) 1 (5.6) 0.222
Recent seroconverters (n539) 25 (64.1) 12 (30.8) 2 (5.1) 0.205
Typical progressors (n575) 45 (60) 26 (34.7) 4 (5.3) 0.227
AIDS progressors (n544) 26 (59.1) 13 (29.5) 5 (11.4) 0.261
Long-term nonprogressors (n542) 26 (61.9) 15 (35.7) 1 (2.4) 0.202
NOTE. SDF1, stromal-derived factor 1 gene. Values are no. (%) unless otherwise
indicated.
a SDF1 genotypes: 1/1, 1/3′A, and 3′A/3′A are wild type, homozygous, and heterozygous
genotypes, respectively.
long-term nonprogressive disease courses. In this study, we ad-
dressed the role of SDF1 polymorphism in a virologically char-
acterized HIV-1–positive population and evaluated the rela-
tionship between SDF1 status and the degree of immune
depletion and non-SI (NSI) or SI HIV-1 phenotype. In addition,
the relationship among HIV-1 replication, phenotype, and
SDF1 genotype was analyzed within a group of highly selected
long-term nonprogressors (LTNPs).
Patients and Methods
Donors and clinical samples. Samples from 105 healthy white
controls living in the Milan area of Italy (80 men and 25 women),
median age 32 years (range, 25–45), were obtained from the Trans-
fusion Service, Department of Immuno-Hematology, L. Sacco
Hospital, Milan. Eighteen female partners repeatedly exposed to
HIV-1 were defined as high-risk persons. In total, 158 HIV-1–in-
fected outpatients of the Institute of Infectious and Tropical Dis-
eases, University of Milan, were consecutively enrolled during
1994–1997. These were classified in three groups: (1) recent sero-
converters (29 men and 10 women, median age 34 years [range,
22–46], with documented seroconversion within 12 months before
the study); (2) typical progressors (59 men and 16 women, median
age 35 years [range, 21–47], with HIV-1 antibodies first detected
during 1988–1994, declining CD4 cell slopes, overall CD4 cell loss
130%, and !500 CD4 cells/mL at enrollment); and (3) 38 men and
6 women with AIDS, according to the 1987 CDC definition (me-
dian age 32 years [range, 21–43]). Median CD4 cell counts per
microliter by group were 537 (range, 317–1735), 230 (range, 1–481),
and 46 (range, 1–209), respectively. All subjects, except those with
AIDS, were naive for antiretroviral therapy. Risk factors for HIV-
1 infection were homosexual contacts ( , 35, and 23), intra-n 5 30
venous drug use (IVDU; , 40, and 21), and heterosexual sexn 5 6
( , 0, and 0) in recent seroconverters, typical progressors, andn 5 3
AIDS patients, respectively. Forty-two subjects (30 men and 12
women, median age 35 years [range, 28–68]) in the Resistant Host
Perspective Study were defined as LTNPs. Risk factors in this group
were homosexual contacts ( ) and IVDU ( ). These sub-n 5 6 n 5 36
jects represent a group of untreated, asymptomatic persons with a
median infection duration of 12 years (range, 10–16) and a CD4
T cell count persistently 1500 cells/mL in a median of 14 consecutive
determinations. They had a median of 725 cells/mL (range,
502–1585) at enrollment in the cohort.
SDF1 polymerase chain reaction (PCR) restriction fragment
length polymorphism. Amplification of the 3′ UTR region of the
SDF1 gene was done by PCR with primers 5′-CAGTCA-
ACCTGGGCAAAGCC-3′ and 5′-AGCTTTGGTCCTGAGAG-
TCC-3′ (nt 779–798 and 1061–1080 of the reference sequence;
GenBank accession number L36033) in a 50-mL final volume, as
described [9]. The reaction mixture contained 200 ng of DNA, 0.2
mM dNTPs, 2 mM MgCl2, 20 pmol of each primer, and 2 U of
Taq polymerase (Perkin-Elmer, Norwalk, CT). Thirty-five cycles
were done as follows: 30 s at 947C, 30 s at 607C, and 2 min at
727C, with a final extension of 10 min at 727C. Cleavage of PCR
products was done by using 5 U of MspI restriction endonuclease
(Sigma, St. Louis) in 20 mL, followed by incubation at 377C for 1
h. The cleavage products and appropriate controls were analyzed
by 2% agarose gel electrophoresis. Genotypic analysis compared
both undigested and digested patient samples. SDF1-1/1, SDF1-
1/3′A, and SDF1-3′A/3′A genotypes were detected as distinct
bands, as follows: 2 bands of 202 and 100 bp; 3 bands of 302, 202,
and 100 bp; and a single band of 302 bp, respectively.
HIV-1 isolation and phenotype evaluation. Peripheral blood
mononuclear cells (PBMC) from HIV-1–infected subjects were iso-
lated by standard gradient-based procedures. HIV-1 was isolated
by cocultivation [15]. HIV-1 p24 antigen was assayed in culture
supernatants by commercial ELISA (DuPont, Wilmington, DE).
Virus phenotype was tested in an MT-2 cell line as described [16].
HIV-1 plasma viremia and specific transcript detection. The
HIV-1 cell-free RNA present in plasma samples and HIV-1 cell-
associated RNA, both unspliced and multiply spliced transcripts,
were quantified by competitive reverse transcription–PCR proce-
dures as described elsewhere [17].
Statistical analysis. Genetic and virologic data were analyzed
by x2 test with Yates’s correction, and Fisher’s exact test was used
to compare proportions between groups. Quantitative molecular
indices of viral activity and CD4 cell values were compared by
Mann-Whitney or Kruskal Wallis tests. The analyses were done
with computer software (StatView version 4.5; Abacus Concepts,
Berkeley, CA).
Results
SDF1 gene polymorphism in subgroups of HIV-1–infected sub-
jects. Table 1 shows the results of SDF1 allele analysis in 123
HIV-1–negative subjects and in 158 consecutively enrolled HIV-
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Table 2. CD4 cell counts and human immunodeficiency virus type
1 (HIV-1) phenotype according to SDF1 polymorphism in a consecutive
series of 158 HIV-1–positive patients.
SDF1
polymorphism
CD4 cells/mL,
median
(range)
HIV-1 phenotype
UND NSI SI
1/1 (n 5 96) 210 (1–1326) 5 (5.2%) 65 (67.7%) 26 (27.1%)
1/3′A (n 5 51) 209 (1–1735) 3 (5.9%) 38 (74.5%) 10 (19.6%)
3′A/3′A (n 5 11) 56 (1–344) 0 9 (81.8%) 2 (18.2%)
P .0449a 1.05b
NOTE. SDF1, stromal-derived factor 1 gene; UND, undetermined pheno-
type in isolation-negative subjects; NSI, non–syncytia-inducing strains; SI, syn-
cytia-inducing strains.
a Kruskal Wallis test.
b
x2 test.
Figure 1. A, Human immunodeficiency virus type 1 (HIV-1) RNA copies/mL. B, Proportion of subjects with HIV-1 isolates with different
phenotypes (UND, undetermined phenotype in isolation-negative subjects; NSI, non–syncytium-inducing strains; SI, syncytium-inducing strains).
C, CD4 cells/mL in SDF1-1/1 and SDF1-1/3′A long-term nonprogressors. * Mann-Whitney test; † x2 test.
1–positive persons (39 recent seroconverters, 75 typical pro-
gressors, and 44 AIDS patients) and 42 LTNPs. A comparable
distribution of each genotype and similar allelic frequency were
observed in the different groups, and no difference in prevalence
of SDF1 polymorphism was seen in 123 HIV-1–negative sub-
jects, compared with the 158 HIV-1–infected patients (59.3%
vs. 60.8%, 37.4% vs. 32.3%, and 3.3% vs. 7% of SDF1-1/1,
SDF1-1/3′A, and SDF1-3′A/3′A status, respectively). Similarly,
the percentages of allele distribution did not differ within HIV-
1–negative or –positive subjects (controls vs. high-risk persons).
Among the consecutively enrolled HIV-1–positive subjects,
those with AIDS had the highest frequency of SDF1-3′A/3′A
genes (11.4%); however, this prevalence was not significantly
different from that of recent seroconverters or typical progres-
sors. A similar frequency of SDF1 polymorphism was observed
in LTNPs. The SDF1 genotypic status was correlated with im-
mune damage, as defined by absolute number of CD4 cells,
and the prevalence of virus variants associated with the pro-
gression of HIV-1 disease, as reflected by HIV-1 phenotype. As
shown in table 2, SDF1-3′A/3′A homozygous status was as-
sociated with the lowest CD4 cell count (median, 56/mL; range,
1–344). There was a weak, albeit significant, difference in CD4
cell numbers among HIV-1–seropositive subjects in the con-
secutive series (recent seroconverters, typical progressors, and
AIDS patients) stratified by SDF1 genotype ( ). InP 5 .0449
contrast, no difference was observed among subjects when con-
sidering HIV-1 phenotype. The proportion of subjects harbor-
ing NSI isolates was similar for each allele status. Of note, 2
subjects with the homozygous mutation of SDF1 harbored SI
variants, suggesting that these patients were not protected from
the NSIrSI shift in the course of HIV-1 infection.
SDF1 polymorphism and HIV-1 activity in LTNPs. Figure
1 illustrates the degree of replication, frequency of virus iso-
lation, and number of CD4 cells in LTNPs stratified by SDF1-
1/1 and SDF1-1/3′A status. As expected, subjects with SDF1
wild type did not differ from those with heterozygous genotype
in CD4 cell counts. Of interest, persons with SDF1-1/1 showed
lower indices of viral activity than those with SDF1-1/3′A.
Median HIV-1 RNA per milliliter of plasma and unspliced and
multiply spliced specific transcripts per PBMC were 26052 3 10
(range, 10–5470), 3 (range, 0–52), and 0 (range, 0–1) and 2019
(range, 100–19,193), 9 (range, 1–218), and 0 (range, 0–22) in
SDF1 wild type and heterozygous subjects, respectively. All
between-group comparisons were statistically significant (P 5
, .016, and .0031 for plasma viremia and unspliced and.0021
multiply spliced transcripts, respectively). One LTNP (2.3%)
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was homozygous for the SDF1-3′A allele; in this subject, HIV-
1 plasma viremia and unspliced and multiply spliced transcripts
in PBMC were 836 copies/mL and 10 and 1 per PBMC,52 3 10
respectively. The P values were not different after the inclusion
of the homozygous SDF1-3′A/3′A subject in the analysis (Krus-
kal Wallis test, , .0416, and .004 for HIV-1 cell-freeP 5 .008
RNA and unspliced and multiply spliced intracellular tran-
scripts, respectively). Fourteen (77.7%) of 18 HIV-negative sub-
jects were SDF1-1/1; the proportion of NSI isolates was not
different in SDF1-1/1 and SDF1-1/3′A subjects. Median age
(35 vs. 35 years), sex (18 men and 8 women vs. 11 men and 4
women), risk groups (24 IVDUs and 2 homosexual contacts
vs. 11 IVDUs and 4 homosexual contacts), and median length
of infection (12 vs. 11 months) were similar in SDF1 wild type
and heterozygous LTNPs.
Discussion
In the last few years, numerous in vivo molecular studies
have indicated that progression to AIDS is strongly associated
with high levels of HIV-1 replication [18, 19]. In this context,
studies that aim to address the correlation between virus load
and the presence of several polymorphisms in HIV-1 coreceptor
genes in vivo are of primary importance. Persons with long-
term nonprogressive courses of HIV-1 infection represent a spe-
cial subset of subjects and enable the study of the complex
interaction between host and viral determinants influencing the
rate of progression and affecting the time-dependent prognosis
of the disease. In these subjects, host factors, including genetic
status and immunologic responses, have been linked to very
slow progression of HIV-1 disease [12, 13, 20, 21].
In addition to CCR5-D32 and CCR2-64I polymorphisms, it
has been postulated that SDF1 polymorphism may assist with
a favorable course of HIV-1 disease. SDF1a may interfere with
T-tropic SI HIV-1 strains by binding and down-regulating the
CXCR4 receptor [8, 22, 23]. It is conceivable that excessive
amounts of full-length SDF1a may occupy the HIV-1 CXCR4
coreceptor and inhibit virus entry. However, no direct evidence
is available at present to support this hypothesis. Moreover,
little is known about the mechanism of action of the isoform
SDF1b, and SDF1b interference in CXCR4 binding of HIV-1
has not been shown. Although the high conservation between
human and murine SDF1b 3′UTRs [24] highlights the impor-
tance of this segment in influencing posttranscriptional pro-
cessing of SDF1b mRNAs, SDF1a and SDF1b 3′UTRs differ
in sequence, and no similarity in the possible function of the
UTRs has been established.
To address the role of SDF1 polymorphism, we analyzed the
frequency of SDF1 polymorphism in a population of HIV-
1–infected patients representing all stages of the disease and in
a group of highly selected LTNPs. The data indicate that SDF1-
3′A/3′A is associated with low CD4 cell counts, and neither
persons with SDF1-3′A/3′A nor those with SDF1-1/3′A are
protected against emergence of SI variants. Two subsets of
LTNPs with distinct patterns of viral activity were identified:
the molecular parameters of HIV-1 replication were signifi-
cantly lower in persons with SDF1-1/1 than in those with
SDF1-1/3′A and those with SDF1-3′A/3′A. Our data are in
agreement with the results of recent studies that considered the
influence of SDF1 allelic status and the outcome of HIV-1 dis-
ease in subjects with a very slow disease progression compared
with that of typical progressors [12, 13]. In particular, the prev-
alence of SDF1-3′A/3′A and SDF1-1/3′A allelic conditions ob-
served in our study within LTNPs was similar to that observed
by Magierowska et al. [12]. Moreover, Hendel et al. [13] found
no significant difference in virus load among slow progressors
stratified by SDF1 polymorphism.
The NSIrSI shift has been recognized as a defined patho-
genic event during HIV-1 disease [25]. It has been suggested
that up-regulation of SDF1a production in SDF1-3′A/3′A and
SDF1-1/3′A patients may prevent the appearance of SI strains
commonly observed in the late phase of HIV-1 infection [9].
However, there has been no direct evidence to demonstrate the
absence of SI strains in persons with SDF1-3′A/3′A. New in-
sights into HIV-1 coreceptor use recently led to a new classi-
fication for HIV-1 strains. Both previous and present findings
concerning HIV-1 cytopathicity and tropism and coreceptor use
may more accurately represent the physiologic behavior of
HIV-1 in the infected host [26]. It is possible that HIV-1 tropism,
defined by the use of CCR5- and CXCR4-expressing cell lines,
may explain our results.
The data from LTNPs shown here deserve specific comment.
First, the protection conferred by the SDF1-3′A allele is not
required for long-term nonprogression, as indicated by the high
percentage of LTNPs with the SDF1-1/1 genotype. Second,
the presence of the 3′A mutation identifies a subset of LTNPs
characterized by significantly more active HIV-1 replication,
even if low to moderate. Because there are conflicting data
regarding the role of the SDF1 homozygous genotype [9–13],
further studies are needed to evaluate whether the immune-
mediated mechanisms involved in controlling viral replication
in SDF1-1/3′A LTNPs are different, on a qualitative or quan-
titative basis, from those in LTNPs without this 3′A mutation.
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